Targeted Systemic Delivery of SDF-1 DNA for the Treatment of Chronic Heart Disease

SDF-1 DNA 的靶向全身递送用于治疗慢性心脏病

基本信息

批准号：
10816900
负责人：
YOUNG-WOOK WON
金额：
$ 4.05万
依托单位：
UNIVERSITY OF NORTH TEXAS
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-06-01 至 2023-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10816900
关键词：
Targeted Systemic Delivery SDF DNA

项目摘要

PROJECT SUMMARY / ABSTRACT Stromal-derived factor-1 (SDF-1)-based gene therapy that can improve mesenchymal stem cell (MSC) homing to the region of myocardial infarct for the treatment of acute myocardial infarction (MI) or chronic heart failure (CHF) has shown considerable promise in preclinical and clinical trials. However, the most established technology requires trans-endocardial injection using a specific device, which can only be handled by an expert. For convenience administration and cost-effective treatment, a targeted systemic delivery strategy has to be developed. In this application, a plasmid DNA encoding SDF-1 will be systemically and specifically delivered to the infarct site by the formation of the SDF-1/ischemic myocardium targeting peptide (IMTP) complex. To generate the SDF-1/IMTP complex, for the first time, we utilize the ligand-to-metal charge transfer transition allowing for direct incorporation of the targeting peptide to the plasmid SDF-1 DNA without the need for any gene carriers. We hypothesized that the LMCT transition between Zn2+ ions and the sulfhydryl group in cysteine of the targeting peptide could spontaneously drive the integration of the peptide to the plasmid SDF-1 that has already been modified to contain Zn2+ ions. It has been known that divalent metal ions, such as Zn2+, lead to the conversion of normal B-DNA to metal-bound DNA (M-DNA) through intercalation into the DNA base pairs in the pH range of 7.0-8.5. In the preliminary studies, we generated M-DNA using Zn2+ ions, confirmed the formation of the M-DNA/targeting peptide complex through the LMCT transition, and demonstrated that the M-DNA/targeting peptide complex led to the enhancement in the gene transfection in the target cells. In this project, in an animal model of CHF, we intend to demonstrate therapeutic efficacy of the targeted systemic delivery of a plasmid SDF-1 DNA by the formation of the SDF-1/IMTP complex generated through the LMCT transition. To achieve the final goal, we intend to demonstrate the followings: 1) direct integration of IMTP into the SDF-1 plasmid through the LMCT transition; 2) targeted transfection of the SDF-1 gene into hypoxic primary cardiomyocytes and the infarct site in the animal model; and 3) facilitated migration of MSCs towards the SDF-1 gradient in the animal model.

项目概要/摘要基于基质衍生因子 1 (SDF-1) 的基因治疗可改善间充质干细胞 (MSC) 归巢到达心肌梗塞区域，用于治疗急性心肌梗塞（MI）或慢性心力衰竭（CHF）在临床前和临床试验中显示出相当大的前景。然而，最成熟的技术需要使用特定设备进行经心内膜注射，该设备只能由专业人员处理专家。为了方便给药和具有成本效益的治疗，有针对性的全身给药策略待开发。在本申请中，编码SDF-1的质粒DNA将被系统地、特异性地通过形成 SDF-1/缺血心肌靶向肽 (IMTP) 递送至梗塞部位复杂的。为了生成 SDF-1/IMTP 复合物，我们首次利用配体到金属的电荷转移转变允许将靶向肽直接掺入质粒 SDF-1 DNA，而不需要对于任何基因携带者。我们假设 Zn2+ 离子和硫氢基之间的 LMCT 跃迁靶向肽的半胱氨酸可以自发驱动肽整合至质粒 SDF-1 已被修改为含有 Zn2+ 离子。众所周知，二价金属离子，例如Zn2+，通过插入 DNA 碱基，导致正常 B-DNA 转化为金属结合 DNA (M-DNA) pH值范围7.0-8.5之间成对。在初步研究中，我们使用 Zn2+ 离子生成 M-DNA，证实通过 LMCT 转变形成 M-DNA/靶向肽复合物，并证明 M-DNA/靶向肽复合物导致靶细胞中基因转染的增强。在这个项目中，我们打算在 CHF 动物模型中证明靶向全身治疗的治疗效果通过 LMCT 生成的 SDF-1/IMTP 复合物的形成来递送质粒 SDF-1 DNA 过渡。为了实现最终目标，我们打算演示以下内容：1）将IMTP直接集成到 SDF-1质粒通过LMCT转变； 2）将SDF-1基因靶向转染至缺氧环境动物模型中原代心肌细胞和梗死部位； 3）促进间充质干细胞向动物模型中的 SDF-1 梯度。